$XBI $127 +1%
Want to access our searchable Catalyst Calendar of over 1,000 biotech stock events and more? Try BiopharmIQ for 30 days free, no credit card required. Check it out here!
Covid Updates
$MRNA +4% UNICEF and Moderna Announce Long Term Agreement to Supply Vaccine on Behalf of the COVAX Facility. source
$SRNE +11% Sorrento Announces Addition of COVI-STIX™ (Covid-19 Virus Rapid Antigen Detection Test) to the Official Mexican Government List of Emergency Use Approved Point of Care Rapid Antigen Tests. source
$MRNA +4% Moderna Announces Agreement with Thermo Fisher Scientific for Fill/Finish Manufacturing of Moderna’s COVID-19 Vaccine. source
Pipeline Updates
$TVTX -1% Travere Therapeutics Completes Enrollment in Pivotal Phase 3 PROTECT Study of Sparsentan in IgA Nephropathy. source
$MTCR -2% Metacrine Achieves Full Enrollment for MET409 Phase 2a Combination Trial in Patients With Type 2 Diabetes and NASH. source
$SLNO +26% Soleno Therapeutics Receives Orphan Drug Designation from FDA for Diazoxide Choline for the Treatment of Glycogen Storage Disease Type 1a. source
$SCYX -15% SCYNEXIS Announces FDA Approval of BREXAFEMME® (ibrexafungerp tablets) as the First and Only Oral Non-Azole Treatment for Vaginal Yeast Infections. source
$BHC -1% $CLSD +7% BAUSCH HEALTH AND CLEARSIDE BIOMEDICAL ANNOUNCE U.S. FDA FILING ACCEPTANCE FOR XIPERE™ (TRIAMCINOLONE ACETONIDE SUPRACHOROIDAL INJECTABLE SUSPENSION). source
$LQDA +6% Liquidia Announces FDA Acceptance of New Drug Application Resubmission for LIQ861 (treprostinil) Inhalation Powder. source
$LOGC +5% LogicBio Therapeutics Announces First Patient Dosed in Groundbreaking Phase 1/2 SUNRISE Clinical Trial for the Treatment of Pediatric Patients Suffering from Methylmalonic Acidemia. source
$KZR -9% Kezar Presents Results of the Completed MISSION Phase 1b Study of KZR-616 at EULAR 2021. source
$KPTI +1% Karyopharm Receives Conditional Marketing Authorization in the United Kingdom (UK) for NEXPOVIO® (selinexor) in Combination with Dexamethasone for the Treatment of Adult Patients with Relapsed and or Refractory Multiple Myeloma. source
$PLX -16% Protalix Biotherapeutics and Chiesi Global Rare Diseases Provide Update Regarding Clinical Development of PRX-102 for Treatment of Fabry Disease. source
Financial Updates
$MOR -12% CNST +66% MorphoSys to Acquire Constellation Pharmaceuticals. source
$LYRA +8% THERAPEUTICS AND LIANBIO ANNOUNCE STRATEGIC PARTNERSHIP AND EXCLUSIVE LICENSE AGREEMENT TO DEVELOP AND COMMERCIALIZE LYR-210 IN GREATER CHINA AND OTHER ASIAN MARKETS. source
Posted by DV